F-star Therapeutics bags $1.5 billion deal with Janssen

20 October 2021

UK and USA-based clinical stage biotech F-star Therapeutics (Nasdaq: FSTX) today announced a license and collaboration agreement with Janssen Biotech, a subsidiary of US healthcare giant of Johnson & Johnson (NYSE: JNJ), which could earn the company more than $1.5 billion.

The agreement was facilitated by Johnson & Johnson Innovation and its announcement saw F-star shares rise as much as 14% to $7.54 in early trading.

Under the terms of the accord, F-star will grant Janssen a worldwide, exclusive royalty-bearing license to research, develop, and commercialize up to five novel bispecific antibodies directed to Janssen therapeutic targets using F-star’s proprietary Fcab and MAb platforms. Janssen will be responsible for all research, development, and commercialization activities under the agreement.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK